Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 10/20 | 0.52 |
| ▸ | SCD | O00767 | 10/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501707 | 0.92 | SCD5 (0.60) | SCD5SCDHSP90AA1HSP90AB1 | |
| SCHEMBL3546279 | 0.89 | SCD5 (0.52) | SCD5SCDHSP90AA1HSP90AB1CCNC | |
| SCHEMBL3548118 | 0.89 | SCD5 (0.54) | SCD5SCDHSP90AA1HSP90AB1 | |
| SCHEMBL3543779 | 0.89 | SCD (0.54) | SCD5SCDHSP90AA1HSP90AB1 | |
| SCHEMBL13501710 | 0.86 | SCD5 (0.48) | SCD5SCDHSP90AA1HSP90AB1 | |
| SCHEMBL3552577 | 0.86 | NPC1 (0.44) | SCD5HSD11B1CCNCCDK8 | |
| SCHEMBL3555052 | 0.85 | SCD5 (0.49) | SCD5SCDHSP90AA1HSP90AB1 | |
| SCHEMBL13501708 | 0.81 | GRM5 (0.53) | SCD | |
| SCHEMBL3545834 | 0.81 | RAB9A (0.52) | SCD5SCDHSD11B1 | |
| SCHEMBL3552295 | 0.80 | SCD (0.48) | SCD5SCDHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | SCD5 1155/4885SCD 599/4885HSD11B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.